RSS-Feed abonnieren
DOI: 10.1055/s-0038-1647847
Plasma Components which Interfere with Ristocetin-induced Platelet Aggregation
Publikationsverlauf
Received 27. November 1974
Accepted 03. März 1975
Publikationsdatum:
02. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/197501/lookinside/thumbnails/10-1055-s-0038-1647847-1.jpg)
Summary
Normal human plasma contains a component or components which interfere with ristocetin-induced platelet aggregation. Preliminary examination suggests a protein (or proteins) which binds ristocetin and competes more effectively for ristocetin than do the proteins involved in ristocetin-induced platelet aggregation. The presence of this protein in normal human plasma also prevents ristocetin-induced precipitation of plasma proteins at levels of ristocetin necessary to produce platelet aggregation (0.5–2.0 mg/ml). Serum contains an apparent two-fold increase of this component when compared with plasma. Heating serum at 56° for one hour results in an additional 2 to 4 fold increase. The presence of a ristocetin-binding protein in normal human plasma requires that this protein be saturated with ristocetin before ristocetin-induced platelet aggregation will occur. Variations in the ristocetin-binding protein(s) will cause apparent discrepancies in ristocetin-induced platelet aggregation in normal human plasmas.
-
References
- 1 Barrow E. M, Graham J. B. Blood coagulation factor VIII (antihemophilic factor) with comments on von Willebrand’s disease and Christmas disease. Physiological Reviews 1974; 54: 23
- 2 Baugh R. F, Brown J, Sargeant R, Hougie C. Separation of human factor VIII activity from von Willebrand’s antigen and ristocetin platelet aggregating activity. Biochimica et Biophysica Acta 1974; 371: 360
- 3 Hougie C, Sargeant R, Brown J. E, Baugh R. F. Evidence that Factor VIII and the ristocetin aggregating factor (VIIIRist) are separate molecular entities. Proceedings of the Society of Experimental Biology and Medicine 1974; 147: 58
- 4 Howard M. A, Firkin G. F. Ristocetin – a new tool in the investigation of platelet aggregation. Thrombosis 1971; 26: 362
- 5 Howard M. A, Sawers R. J, Firkin B. G. Ristocetin: a means of differentiating von Willebrand’s disease into two groups. Blood 1973; 41: 687
- 6 Laurell C. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 1960; 15: 45
- 7 Pool J. G, Shannon A. W. Production of high-potency concentrates of antihemophilic globulin in a closed bag system. New England Journal of Medicine 1965; 273: 1443
- 8 Walsh P. N. Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. British Journal of Hematology 1972; 22: 205
- 9 Weiss H, Rogers J, Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand’s disease and its correction by factor VIII. Journal of Clinical Investigation 1973; 52: 2697
- 10 Weiss H. J, Hoyer L, Rickles R, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. Journal of Clinical Investigation 1973; 52: 2708
- 11 Zimmerman T, Ratnoff O, Powell A. E. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease. Journal of Clinical Investigation 1971; 50: 244